No matches
Pulmonology

Why Is It Important to Assess Lung Function in Pediatric Asthma

Learn about FEV1pp and the downstream effects of lung function decline in children with severe asthma

Learning objectives

  • Understand the importance of lung function assessment

Description

Learn about FEV1pp, how type 2 inflammation results in lung function impairment, and about the downstream effects of lung function decline in children with severe asthma.

Tags
biomarkersexacerbationsfev1lung functionpediatrictype 2 inflammation
MAT-GLB-2200523 - 3.0 - 03/2024

Related resources

How Can Biologics Improve Lung Function in Pediatric Severe Asthma?
Pulmonology
expert video

How Can Biologics Improve Lung Function in Pediatric Severe Asthma?

EAACI 2023 | Pediatric Severe Asthma: Why Lung Function Matters
Pulmonology
expert video

EAACI 2023 | Pediatric Severe Asthma: Why Lung Function Matters

Type 2 Inflammation Underpins Pediatric Severe Asthma
Pulmonology
Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

Why Is It Important to Assess Lung Function in Pediatric Severe Asthma Patients?
Pulmonology
expert video

Why Is It Important to Assess Lung Function in Pediatric Severe Asthma Patients?

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age
Pulmonology
interactivity

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?
Pulmonology
Podcast

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma
Pulmonology
Podcast

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

Eosinophils as a Biomarker for Type 2 Asthma
Pulmonology
expert video

Eosinophils as a Biomarker for Type 2 Asthma

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13
Pulmonology
expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

ERS 2024 | Understanding the Complex Pathophysiology of COPD
Pulmonology
expert video

ERS 2024 | Understanding the Complex Pathophysiology of COPD

COPD and Asthma: What's the Difference and Is There a Link?
Pulmonology
interactivity

COPD and Asthma: What's the Difference and Is There a Link?

Type 2 Inflammation Digital Assessment Tool
Pulmonology
interactivity

Type 2 Inflammation Digital Assessment Tool

What Are the Key Inflammatory Processes in Patients with COPD?
Pulmonology
expert video

What Are the Key Inflammatory Processes in Patients with COPD?

FeNO as a Biomarker for Type 2 Asthma
Pulmonology
expert video

FeNO as a Biomarker for Type 2 Asthma

IgE as a Biomarker for Type 2 Asthma
Pulmonology
expert video

IgE as a Biomarker for Type 2 Asthma

Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management
Pulmonology
interactivity

Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management

Pediatric Asthma Patient Case Tool: Ash
Pulmonology
interactivity

Pediatric Asthma Patient Case Tool: Ash

The Cycle of Inflammation in Adult Asthma
Pulmonology
interactivity

The Cycle of Inflammation in Adult Asthma

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma
Pulmonology
Infographic

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients
Pulmonology
expert video

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

What is the Role of FeNO as an Asthma Biomarker?
Pulmonology
expert video

What is the Role of FeNO as an Asthma Biomarker?

ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?
Pulmonology
expert video

ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?

ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond
Pulmonology
Podcast

ADVENT On Air | Breathing Easy: Navigating Lung Function in Pediatric Severe Asthma With Spirometry and Beyond

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients
Pulmonology
Infographic

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients

Blood Eosinophils: A Biomarker in COPD
Pulmonology
Infographic

Blood Eosinophils: A Biomarker in COPD

Pathways to Disease: Inflammation in COPD
Pulmonology
interactivity

Pathways to Disease: Inflammation in COPD

What Do We Know About Type 2 Inflammation in COPD?
Pulmonology
expert video

What Do We Know About Type 2 Inflammation in COPD?

What Differentiates COPD Exacerbations From Asthma Exacerbations?
Pulmonology
expert video

What Differentiates COPD Exacerbations From Asthma Exacerbations?

The Heterogeneity of Underlying Inflammation in Patients With COPD
Pulmonology
expert video

The Heterogeneity of Underlying Inflammation in Patients With COPD

ERS 2023 | Contextualizing Clinical Presentation of COPD Through Disease Pathology
Pulmonology
expert video

ERS 2023 | Contextualizing Clinical Presentation of COPD Through Disease Pathology

ERS 2023 | Heterogeneity of Inflammatory Pathways in COPD
Pulmonology
expert video

ERS 2023 | Heterogeneity of Inflammatory Pathways in COPD

ERS 2024 | What Do We Know About IL-33 Genetics?
Pulmonology
expert video

ERS 2024 | What Do We Know About IL-33 Genetics?

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video
Pulmonology
videoanimation

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?
Pulmonology
expert video

ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

ADVENT On Air | Diving Deep: Exploring the Impact of Airway Remodeling in Severe Asthma
Pulmonology
Podcast

ADVENT On Air | Diving Deep: Exploring the Impact of Airway Remodeling in Severe Asthma

ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Introduction
Pulmonology
expert video

ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Introduction

ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma
Pulmonology
expert video

ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden
Pulmonology
expert video

ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden

ERS 2024 | Fireside Chat: What Is the Potential for Disease Modification in the Era of Biologics?
Pulmonology
expert video

ERS 2024 | Fireside Chat: What Is the Potential for Disease Modification in the Era of Biologics?

ERS 2024 | Perspectives From the Evolving Biologic Landscape in COPD
Pulmonology
expert video

ERS 2024 | Perspectives From the Evolving Biologic Landscape in COPD

Why Is It Important to Assess Lung Function in Pediatric Asthma
Pulmonology
interactivity

Why Is It Important to Assess Lung Function in Pediatric Asthma

What Is The COPD Vicious Cycle?
Pulmonology
expert video

What Is The COPD Vicious Cycle?

Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline
Pulmonology
videoanimation

Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline

Tailored Medicine in COPD: Understanding Phenotypes, Endotypes, and Genotypes
Pulmonology
interactivity

Tailored Medicine in COPD: Understanding Phenotypes, Endotypes, and Genotypes

ADVENT On Air | Pulmonary Perspectives: Understanding COPD Patient Burden
Pulmonology
Podcast

ADVENT On Air | Pulmonary Perspectives: Understanding COPD Patient Burden

ADVENT On Air | Role of Type 2 Inflammation in COPD
Pulmonology
Podcast

ADVENT On Air | Role of Type 2 Inflammation in COPD

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control
Pulmonology
expert video

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

ERS 2024 | IL-33 A Promising Target
Pulmonology
expert video

ERS 2024 | IL-33 A Promising Target

ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling
Pulmonology
expert video

ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling

ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management
Pulmonology
expert video

ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: EcuadorChange country/region